Genentech’s Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)
View original at finance.yahoo.comGenentech’s Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS) – Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to…
O que extraímos desta fonte
The claims Via News extracted from this document. We point to the source; we don't replace it.
Multiple sclerosis affects more than 2.9 million people worldwide
80% confidenceApproximately 85% of people with multiple sclerosis have a relapsing form of the disease
80% confidenceFenebrutinib has a selectivity for BTK 130 times greater than other kinases
80% confidenceFenebrutinib represents the first potential scientific breakthrough for the PPMS community in over a decade, demonstrating a meaningful clinical benefit in reducing disability progression
80% confidencePost-hoc analysis showed fenebrutinib was superior to Ocrevus on a composite endpoint including EDSS and 9HPT, with a 22% reduction in risk
80% confidenceFenebrutinib has the potential to become first-in-class in multiple sclerosis as an oral, brain-penetrant BTK inhibitor for PPMS and RMS
80% confidenceFenebrutinib showed a 12% reduction in the risk of disability progression compared to Ocrevus as measured by time to onset of 12-week composite confirmed disability progression
80% confidenceOcrevus is the only approved treatment for PPMS
80% confidenceMore than 2,700 patients and healthy volunteers have been treated with fenebrutinib in Phase I, II and III clinical programs across multiple diseases
80% confidenceTreatment effect curves separated as early as 24 weeks in the FENtrepid study
80% confidenceFenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis
80% confidenceFenebrutinib met its primary endpoint of non-inferiority compared to Ocrevus in reducing disability progression in PPMS patients
80% confidenceFenebrutinib showed strongest treatment effect on the risk of worsening on the 9HPT by 26% compared to Ocrevus
80% confidenceFenebrutinib has the potential to be a high-efficacy, oral treatment option that acts directly in the brain, targeting progressive biology, and may slow disability
80% confidenceFenebrutinib showed a consistent clinical benefit as early as week 24, notably in upper limb function, which is essential for preserving independence and daily functioning
80% confidenceApproximately 15% of people with multiple sclerosis are diagnosed with the primary progressive form
80% confidence